STK11 loss and SMARCB1 deficiency mutation in a dedifferentiated lung cancer patient present response to neo-adjuvant treatment with pembrolizumab and platinum doublet: A case report

Cancers harboring serine threonine kinase (STK11) alteration or SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1 (SMARCB1) mutation are conventionally considered as treatment-refractory to immune checkpoint inhibitors or chemotherapy, respectively. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jianxin, Wang, Junhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911826/
https://www.ncbi.nlm.nih.gov/pubmed/36776287
http://dx.doi.org/10.3389/fonc.2023.1088534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911826/
https://www.ncbi.nlm.nih.gov/pubmed/36776287
http://dx.doi.org/10.3389/fonc.2023.1088534

Ejemplares similares